Review highlights biomarkers for transplant rejection in organ transplantation, indicating evolving diagnostic tools.
Every year, the incidence of heart, liver, and kidney transplants rises. This is due to robust transplant networks, improvements in procurement strategies, and advances in surgical techniques. However, long-term transplant rejection monitoring and diagnosis continue to rely on biopsy confirmation. We review the latest updates on biomarkers of transplant rejection. These include donor-specific antibodies, which are now routinely in use, and cell-free DNA and microRNA, which are still being tested for their diagnostic efficacy. This review aims to serve as a reference tool for providers as the field continues to evolve and improve outcomes in transplant care.
No takes yet. Share an insight, caveat, or question.
Mushannen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: